1. Guselkumab therapy shows improvement in Crohn's disease over 48 weeks.
2. Combined data from GALAXI-2 and GALAXI-3 trials.
3. Significant clinical response in guselkumab vs. placebo groups.
4. Most achieving remission were corticosteroid-free for over 90 days.
5. Serious adverse events occurred, no deaths reported.
6. Efficacy observed as early as week 4 after treatment.
7. Balanced results in biologic-naive and prior-intolerance patients.

Source: The Lancet